Pay vs Performance Disclosure - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
As required by Section 953(a) of the Dodd-Frank Act, and Item 402(v) of Regulation S-K, we are providing the following information about the relationship between executive “compensation actually paid” and certain financial performance of the Company. For further information concerning the Company’s pay-for-performance philosophy and how the Company aligns executive compensation with the Company’s performance, refer to the “Compensation Discussion and Analysis” section above.
| Value of Initial Fixed $100 Investment Based On: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Year | Summary Compensation Table Total for PEO ($)(1) | Compensation Actually Paid to PEO ($)(2) | Average Summary Compensation Table Total for Non-PEO NEOs ($)(3) | Average Compensation Actually Paid to Non- PEO NEOs ($)(2) | Total Stockholder Return ($)(4) | Peer Group Total Stockholder Return ($)(5) | Net Income (Loss) ($ in thousands)(6) | ORLADEYO Sales ($ in thousands)(7) | ||||||||||||||||||||||||||||||||||||||||||
| 2024 | 8,317,286 | 10,979,333 | 3,368,257 | 4,160,611 | 217.97 | 172.62 | (88,881) | 434,090 | ||||||||||||||||||||||||||||||||||||||||||
| 2023 | 4,777,778 | (3,691,891) | 1,963,725 | (1,232,421) | 173.62 | 159.01 | (226,539) | 323,812 | ||||||||||||||||||||||||||||||||||||||||||
| 2022 | 6,982,994 | 4,009,070 | 2,568,935 | 1,452,633 | 332.75 | 153.08 | (247,116) | 249,689 | ||||||||||||||||||||||||||||||||||||||||||
| 2021 | 7,061,225 | 17,053,230 | 4,523,739 | 7,254,142 | 401.45 | 137.47 | (184,062) | 121,865 | ||||||||||||||||||||||||||||||||||||||||||
| 2020 | 6,034,941 | 10,853,629 | 2,353,552 | 3,630,213 | 215.94 | 110.52 | (182,814) | 133 | ||||||||||||||||||||||||||||||||||||||||||
______________________
(1)These amounts represent the amounts reported for our CEO, Jon P. Stonehouse, in the “Total” column of the Summary Compensation Table in each applicable year.
(2)These amounts represent the amount of “compensation actually paid” to Mr. Stonehouse and the average “compensation actually paid” to the Company’s other NEOs (as described in footnote (3)) as a group, as computed in accordance with Item 402(v) of Regulation S-K, and do not reflect the total compensation actually realized or received by Mr. Stonehouse or the other NEOs. In accordance with these rules, these amounts reflect total compensation as set forth in the Summary Compensation Table for each year, adjusted as shown below. Equity values are calculated in accordance with FASB ASC Topic 718, and the valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant.
| Compensation Actually Paid | Mr. Stonehouse 2024 ($) | Average Non-PEO NEOs 2024 ($) | ||||||||||||
| Summary Compensation Table Total | 8,317,286 | 3,368,257 | ||||||||||||
| (Less), value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table | (6,678,053) | (2,274,445) | ||||||||||||
| Plus, year-end fair value of outstanding and unvested equity awards granted in the year | 6,818,576 | 2,322,304 | ||||||||||||
| Plus (less), year-over-year change in fair value of outstanding and unvested equity awards granted in prior years | 1,507,716 | 520,381 | ||||||||||||
| Plus (less), change in fair value from the end of the prior year to the vesting date of equity awards granted in prior years that vested in the year | 1,013,808 | 224,114 | ||||||||||||
| Compensation Actually Paid | 10,979,333 | 4,160,611 | ||||||||||||
(3)These amounts represent the average of the amounts reported for the Company’s named executive officers (referred to as “NEOs” in this section) as a group (excluding Mr. Stonehouse) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs included for these purposes in each applicable year are as follows: (i) for 2024 and 2023, Mr. Doyle, Dr. Thackray, Ms. Barnes, and Mr. Gayer; (ii) for 2022, Mr. Doyle, Dr. Thackray, Ms. Barnes, Mr. Gayer, Yarlagadda S. Babu, Ph.D., the Company’s Chief Discovery Officer, and William P. Sheridan, MBBS, the Company’s Chief Development Officer; (iii) for 2021, Mr. Doyle, Dr. Thackray, Dr. Babu, Dr. Sheridan, and Megan T. Sniecinski, the Company’s former Chief Business Officer; and (iv) for 2020 Thomas R. Staab II, the Company’s former CFO, Mr. Doyle, Dr. Babu, Dr. Sheridan, and Ms. Sniecinski. Refer to the “2023 Summary Compensation Table,” “2022 Summary Compensation Table,” “2021 Summary Compensation Table” and “2020 Summary Compensation Table” in our proxy statements for our 2024, 2023, 2022, and 2021 annual stockholder meetings, respectively, for additional information regarding our NEOs for 2023, 2022, 2021 and 2020, respectively.
(4)Total Stockholder Return (TSR) measures the change in a $100 investment in our Common Stock based on its closing price of $3.45 on December 31, 2019 and the closing share price of our Common Stock at the end of each fiscal year shown.
(5)The peer group used for this purpose is the CRSP Total Return Index for Nasdaq Pharmaceutical Stocks.
(6)The dollar amounts reported represent the amount of net loss reflected in the Company’s audited financial statements for the applicable year.
(7)Item 402(v)(2)(vi) of Regulation S-K requires that we designate a “Company-Selected Measure,” which, in our assessment, represents the most important financial performance measure (that is not otherwise required to be disclosed in the “Pay Versus Performance” table) used to link “compensation actually paid” to our NEOs, for the most recently completed fiscal year, to Company performance. For these purposes, we have
selected ORLADEYO sales. The numbers in this column represent product sales of ORLADEYO and do not include royalty revenue from sales of ORLADEYO in Japan by our collaborative partner, Torii Pharmaceutical Co., Ltd. ORLADEYO is an oral, once-daily therapy discovered and developed by us for the prevention of hereditary angioedema attacks. It was first approved by the U.S. Food and Drug Administration in December 2020, and we began shipping it to patients with a prescription in the United States that same month.
| Compensation Actually Paid | Mr. Stonehouse 2024 ($) | Average Non-PEO NEOs 2024 ($) | ||||||||||||
| Summary Compensation Table Total | 8,317,286 | 3,368,257 | ||||||||||||
| (Less), value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table | (6,678,053) | (2,274,445) | ||||||||||||
| Plus, year-end fair value of outstanding and unvested equity awards granted in the year | 6,818,576 | 2,322,304 | ||||||||||||
| Plus (less), year-over-year change in fair value of outstanding and unvested equity awards granted in prior years | 1,507,716 | 520,381 | ||||||||||||
| Plus (less), change in fair value from the end of the prior year to the vesting date of equity awards granted in prior years that vested in the year | 1,013,808 | 224,114 | ||||||||||||
| Compensation Actually Paid | 10,979,333 | 4,160,611 | ||||||||||||
| Compensation Actually Paid | Mr. Stonehouse 2024 ($) | Average Non-PEO NEOs 2024 ($) | ||||||||||||
| Summary Compensation Table Total | 8,317,286 | 3,368,257 | ||||||||||||
| (Less), value of “Stock Awards” and “Option Awards” reported in Summary Compensation Table | (6,678,053) | (2,274,445) | ||||||||||||
| Plus, year-end fair value of outstanding and unvested equity awards granted in the year | 6,818,576 | 2,322,304 | ||||||||||||
| Plus (less), year-over-year change in fair value of outstanding and unvested equity awards granted in prior years | 1,507,716 | 520,381 | ||||||||||||
| Plus (less), change in fair value from the end of the prior year to the vesting date of equity awards granted in prior years that vested in the year | 1,013,808 | 224,114 | ||||||||||||
| Compensation Actually Paid | 10,979,333 | 4,160,611 | ||||||||||||
Compensation Actually Paid, Cumulative TSR, and Peer Group TSR
Compensation Actually Paid and Net Loss
Compensation Actually Paid and ORLADEYO Sales
Compensation Actually Paid, Cumulative TSR, and Peer Group TSR
Performance Measures
As disclosed above under “Description of Certain Relationships between Information Presented in the Pay Versus Performance Table,” the Company uses several performance measures to align executive compensation with Company performance, not all of which are presented in the “Pay Versus Performance” table. These performance measures include the pre-established corporate objectives for 2024, as described in the “Compensation Discussion and Analysis” section, and reflect the Company’s variable pay-for-performance philosophy. As a growing company that engages heavily in research and development, the majority of our corporate objectives were not “financial performance measures,” as defined by SEC rules. However, they did include one financial performance measure for ORLADEYO sales. Accordingly, the most important financial performance measure used by the Company to link executive “compensation actually paid” to the Company’s NEOs, for the most recently completed fiscal year, to the Company’s performance is as follows:
•ORLADEYO sales.
In addition to our financial performance measure, the Company views stock price as a key driver of value for all of our equity awards and, in particular, the stock options, which have no value unless the stock price appreciates from the date of grant.
Description of Certain Relationships between Information Presented in the Pay Versus Performance Table
As described in more detail in the “Compensation Discussion and Analysis” section above, the Company’s executive compensation program reflects a variable-pay-for-performance philosophy. It is based on market best practices and is designed to ensure that it is appropriately risk-based and competitive with similar companies in our industry. The Company’s primary objectives for our executive compensation program are described on page 27 of the “Compensation Discussion and Analysis,” and the pre-established corporate objectives used to determine the variable component of executive compensation for 2024 (i.e., cash bonus under the AIP and 2024 long-term equity grants) are described on page 31. While the Company uses several performance measures to align executive compensation with Company performance, not all of those Company measures are presented in the “Pay Versus Performance” table above. Further, not all of the Company’s performance measures are “financial performance measures” as defined above in note 7 to the “Pay Versus Performance” table. For example, as a growing commercial-stage biotechnology company with the goal of developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics, some of our performance measures relate to developments in the Company’s product pipeline and to building a robust and adaptable organization. The Company generally seeks to incentivize long-term performance of the Company as a whole and, therefore, does not specifically align the Company’s performance measures with “compensation actually paid” (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year, which can be impacted in large part by changes in stock price. The Compensation Committee does not consider the information presented in this “Pay Versus Performance” section when making determinations regarding executive compensation.